Pharma Research and Early Development, F.Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH4070, Basel, Switzerland.
Amgen Research, 360 Binney St, Cambridge, MA 02141, USA.
Lab Chip. 2020 Feb 7;20(3):446-467. doi: 10.1039/c9lc00857h. Epub 2020 Jan 14.
Over the last decade, progress has been made on the development of microphysiological systems (MPS) for absorption, distribution, metabolism, and excretion (ADME) applications. Central to this progress has been proof of concept data generated by academic and industrial institutions followed by broader characterization studies, which provide evidence for scalability and applicability to drug discovery and development. In this review, we describe some of the advances made for specific tissue MPS and outline the desired functionality for such systems, which are likely to make them applicable for practical use in the pharmaceutical industry. Single organ MPS platforms will be valuable for modelling tissue-specific functions. However, dynamic organ crosstalk, especially in the context of disease or toxicity, can only be obtained with the use of inter-linked MPS models which will enable scientists to address questions at the intersection of pharmacokinetics (PK) and efficacy, or PK and toxicity. In the future, successful application of MPS platforms that closely mimic human physiology may ultimately reduce the need for animal models to predict ADME outcomes and decrease the overall risk and cost associated with drug development.
在过去的十年中,微生理系统(MPS)在吸收、分布、代谢和排泄(ADME)应用方面取得了进展。这一进展的核心是学术和工业机构生成的概念验证数据,随后进行了更广泛的特征研究,为药物发现和开发的可扩展性和适用性提供了证据。在这篇综述中,我们描述了一些特定组织 MPS 的进展,并概述了这些系统所需的功能,这些功能可能使它们适用于制药行业的实际应用。单一器官 MPS 平台将有助于模拟组织特异性功能。然而,只有使用相互关联的 MPS 模型才能获得动态器官串扰,特别是在疾病或毒性的情况下,这将使科学家能够解决药代动力学(PK)和疗效或 PK 和毒性交叉点的问题。在未来,成功应用更接近人类生理学的 MPS 平台最终可能减少对动物模型预测 ADME 结果的需求,并降低药物开发相关的整体风险和成本。